$CRL

Madison Small Cap Fund outperformed benchmarks in Q3 2026, with healthcare and technology sectors driving gains. Charles River Laboratories (CRL) was highlighted as a strong performer, with a 21.18% one-month return. The fund focuses on high-quality companies with strong fundamentals. CRL's stock traded between $146.20 and $357.77 over 52 weeks, closing at $357.35 on October 26, 2026.

Group 1 Automotive (GPI) saw a $24.2M insider purchase by Conifer Management, while Corebridge Financial (CRBG) had an $8.7M buy by Nippon Life. Optimum Communications (OPTU) and Korro Bio (KRRO) also reported insider buys. Gentherm (THRM) had a $532.6K purchase. On the sell side, Intuitive Surgical (ISRG), Charles River Labs (CRL), Lam Research (LRCX), United Therapeutics (UTHR), and PACS Group (PACS) reported insider sales.

FOSTER JAMES C sold 24,042 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $350.00 ($8.41M total) on 2026-10-22 under a Rule 10b5-1 trading plan.

Parisotto Shannon M (CEVP, Disc & Safety Assessment) sold 2,156 shares of CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) at $344.41 ($0.74M total) on 2026-10-21 under a Rule 10b5-1 trading plan.

Charles River Laboratories (NYSE:CRL) partnered with the FDA and Labcorp to develop tools for assessing drug abuse potential. The collaboration aims to standardize metrics for preclinical abuse potential evaluations, using behavioral economic models. Charles River has conducted over 100 such studies and contributed to 15 FDA-approved products.

Charles River Laboratories (CRL) stock rose 8.5% on regulatory relief and bullish sentiment. The company's stock broke out of a $290–$310 range, closing near $343. CRL reported $4.0B in annual revenue, with a 32.7% gross margin. Analysts raised price targets, citing margin expansion and growth plans. The next earnings call is scheduled for November 4, 2026.

Charles River Laboratories (CRL) has partnered with Magellan Stem Cells to advance the development of Zelestrocel, a stem cell therapy for osteoarthritis. CRL will provide GMP-compliant testing services, including viral safety assessments. Magellan recently completed Phase I/II trials and is preparing for Phase III. The partnership aims to accelerate Zelestrocel's path to commercialization, adhering to international regulatory standards.

Azenta reported Q2 revenues of $161.2M, up 12% YoY, beating estimates. IQVIA reported $4.37B in revenues, up 8.7% YoY, exceeding expectations. Charles River Laboratories reported $1.00B in revenues, down 2.7% YoY, but beating estimates. Repligen reported $204.1M in revenues, up 11.9% YoY, also beating estimates. All stocks have seen significant gains since reporting.

Charles River Laboratories (CRL) launched Apollo Orchestrate, a digital platform to streamline GMP QC workflows in North America and Europe. The system integrates Apollo and LabWare LIMS for enhanced traceability. According to the company, the move supports its digitization efforts in Biologics Testing Solutions.

Charles River Laboratories (CRL) and Autolomous launched Apollo Orchestrate™, a digital laboratory execution system. It connects and digitizes lab workflows, enhancing efficiency and transparency. The system is deployed across North America and Europe for QC testing. CRL aims to modernize lab workflows, while Autolomous's autoloMATE platform enables digital integration and cost savings.